Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral
corticosteroid use than placebo in outpatients with severe asthma and moderate or severe
major depressive disorder (MDD). 2) Escitalopram treatment will be associated with greater
improvement in asthma symptoms than placebo in outpatients with severe asthma and moderate or
severe MDD. 3) Escitalopram treatment will be associated with greater depressive symptom
remission rates than placebo in outpatients with severe asthma and moderate or severe MDD.